{"paper_id": "873d4a5567eca345d5ed760eccd2924022282e15", "metadata": {"title": "Supplemental information: HIER -Heat-induced epitope retrieval 636 DAB -3,3'-Diaminobenzidine (produces brown stain) AEC -aminoethyl carbazole (produces red stain) Counterstain -Harris hematoxylin (blue color)", "authors": []}, "abstract": [{"text": "559 560 Supplemental Figure 1. Single-cell RNA sequencing reanalyses of ACE2 transcript abundance 561 in lung parenchyma (23). Summative observations from all donors. a) Uniform manifold 562 approximation and projection (UMAP) visualizations. Cells were clustered using a shared 563 nearest neighbor (SNN) approach. Cell types associated with each cluster were identified by 564 determining marker genes for each cluster. Each data point denotes a cell. On the right panel, 565 cells with ACE2 transcripts are shown in red. b) Violin plots representing ACE2 expression in 566 the alveoli. Airway cells (basal, mitotic, ciliated, club) are not shown. Percentage of ACE2 + cells 567 within each cell type shows ACE2 transcripts in 1.2% of alveolar type II cells and in 0.1% of 568 macrophages, monocytes, or dendritic cells. Each data point denotes a cell, most cells have no 569 expression (0). AT2: alveolar type II. AT1: alveolar type I. Macs: Macrophages. Mono: 570 Monocytes. DC: dendritic cells. Other immune cells: B cells, mast cells, natural killer/T cells.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "cluster that were used to assign cell types.", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": ". CC-BY-ND 4.0 International license was not certified by peer review) is the author/funder. It is made available under a The copyright holder for this preprint (which this version posted June 1, 2020. ", "cite_spans": [], "ref_spans": [], "section": "614"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "CA); 1:60,0000/30 min HIER, Citrate buffer pH 6.0, 110\u02daC for 15min", "authors": [{"first": "", "middle": [], "last": "Inc", "suffix": ""}, {"first": "C", "middle": ["A"], "last": "Carpentaria", "suffix": ""}, {"first": "", "middle": [], "last": "Usa)", "suffix": ""}, {"first": "", "middle": [], "last": "Chromogen", "suffix": ""}], "year": null, "venue": "counterstain. MUC5B Rabbit anti-MUC5B polyclonal, (LSBio #LS-B8121", "volume": "1", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "USA) in diluent 1:100 x 1 hour HIER, Citrate Buffer, pH 6.0, 110\u02daC for 15 minutes", "authors": [{"first": "-Sp-C", "middle": [], "last": "Anti", "suffix": ""}], "year": null, "venue": "Biocare Medical", "volume": "", "issn": "", "pages": "5--71680", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Representative tissue section from submucosa of large airways 576 (trachea/bronchi) showing ACE2 protein localization (brown color, black arrows) (a, b) and 577 scores (c). a) Submucosal glands had uncommon to localized apical ACE2 protein (arrows) in 578 serous (S) cells, but not mucous (M) cells. b) Submucosal glands also had absent to uncommon 579 ACE2 protein (arrows) in the interstitium that centered on vascular walls and endothelium. This 580 vascular staining was uncommonly seen in lung too and corresponded to the low levels seen in 581 transcripts for these endothelial cells (Supplemental Figure 1a-b). Note the absence of ACE2 582 staining in serous (S) or mucous (M) cells of the gland (b). c) ACE2 protein scores for each 583 subject for serous cells in submucosal glands from trachea and bronchi, in control versus chronic 584 disease groups (P>0.9999, 0.9999, respectively, Mann-Whitney U test). Bar = 25 \u03bcm. LOD: 585 Limit of detection.", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Single-cell RNA sequencing reanalyses of ACE2 transcript abundance 589 in nasal brushing (a, b) and nasal turbinate (c, d) (24). a, c) Uniform manifold approximation 590 and projection (UMAP) visualizations. Cells were clustered using a shared nearest neighbor 591 (SNN) approach. Cell types associated with each cluster were identified by determining marker 592 genes for each cluster. Each data point denotes a cell. On the right panels, cells with ACE2 593 transcripts are shown in red. b, d) Violin plots representing ACE2 expression. In nasal turbinate 594 and nasal brushing, percentage of ACE2 + cells within each cell type shows ACE2 expression on 595 epithelial cells. Each data point denotes a cell, most cells have no expression (0). DC: dendritic 596 cells. NK: Natural killer. CPM: Counts per million.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Quality controls for ACE2 immunohistochemistry technique (a, b) and 600 tissue quality (c, d). a, b) ACE2 protein (brown color, black arrows) was detected along the 601 apical surface of small intestine enterocytes (a), renal tubule epithelium (b), and ciliated cells (b, 602 inset) of primary airway cell cultures. These findings demonstrate specific detection of ACE2 603 protein in cells/tissues consistent with known ACE2 expression. c) Representative 604 immunostaining of bronchus detected abundant MUC5B protein (brown color, black arrows) in 605 mucous cells of surface epithelium (top) and submucosal glands (bottom). d) Representative 606 sections of alveoli had SP-C + alveolar type II cells (red color, red arrows). These results (c, d) 607 demonstrate the tissues were intact and that immunostaining can be used to detect native airway 608 (c) and lung (d) proteins. Bar = 40 (a, b), 80 (c), and 20 \u03bcm (d).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Single-cell RNA sequencing reanalyses of lung parenchyma (a) (23), 612 nasal brushing (b) and nasal turbinate (c) (24). Heatmaps depicting the marker genes for each 613", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Tissues: Sinonasal (SN), trachea (T), bronchi (B), bronchioles (Br), and alveoli (Al) 620 Cellular localization: cytoplasmic (C), nuclear (N), apical membrane (A) 621 Cells: Surface epithelium (SE), alveolar type I cells (AT1), alveolar type II cells (AT2)", "latex": null, "type": "figure"}, "TABREF0": {"text": "Supplemental Table 1. ACE2 protein reported in surface epithelium (SE) of human respiratory tract surface epithelium.Non-diseased: The cause of death was not directly related to lung disease 618 n.d.: Not described", "latex": null, "type": "table"}, "TABREF1": {"text": "SupplementalTable 2. Donor demographics and ACE2 distribution scores for each tissue NA: Not available for analyses / COPD: Chronic obstructive pulmonary disease / NASH: Nonalcoholic steatohepatitis. Scoring: 0 = below limit of immunohistochemical detection; 1 = rare (<1%); 2 = 1-33%; 3 = 34-BY-ND 4.0 International license was not certified by peer review) is the author/funder. It is made available under aThe copyright holder for this preprint (which this version posted June 1, 2020. . https://doi.org/10.1101/2020.04.22.056127 doi: bioRxiv preprint", "latex": null, "type": "table"}, "TABREF2": {"text": "Table 1. ACE2 protein reported in surface epithelium (SE) of human 615 respiratory tract surface epithelium. 616", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Reported Cases [n] </td><td>Primary Ab </td><td>SN </td><td>T </td><td>B </td><td>Br </td><td>Al </td><td>Summary comments </td></tr><tr><td>Non-diseased lungs / nasal </td><td>Polyclonal </td><td>SE (C++, basal cells </td><td>n.d. </td><td>SE (C+) </td><td>n.d. </td><td>AT1 (C++); </td><td>Abundant ACE2 protein in lung epithelia </td></tr><tr><td>[5 each]; </td><td>\u00a0</td><td>in </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>AT2 (C++) </td><td>\u00a0</td></tr><tr><td>diseased lungs [5] (17) </td><td>squamous epithelium) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Non-diseased </td><td>Undefined </td><td>n.d. </td><td>SE </td><td>SE (C+, </td><td>n.d. </td><td>\"Alveoli\" </td><td>ACE2 is present on epithelia in several parts of the respiratory tract and macrophages </td></tr><tr><td>lungs [5] (18) </td><td>\u00a0</td><td>(C+, </td><td>A+) </td><td>\u00a0</td><td>(A+) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>A+) </td><td>\u00a0</td><td>\u00a0</td><td>Mac (A+) </td></tr><tr><td>Lung [undefined] </td><td>Polyclonal </td><td>n.d. </td><td>n.d. </td><td>SE (C+, N+, M+) </td><td>n.d. </td><td>AT1 \u0336\nAT2 (N+) </td><td>ACE2 is present in bronchial </td></tr><tr><td>(19) </td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>epithelium, AT2 cells and macrophages </td></tr><tr><td>Sinus [undefined] and Lung [undefined, same tissues </td><td>Polyclonal </td><td>SE (N++) </td><td>SE ( ) </td><td>SE (C+, N++) </td><td>n.d. </td><td>AT1 \u0336\nAT2 </td><td>ACE2 is present in sinus and </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>(N++) </td><td>bronchial epithelium, AT2 cells and macrophages </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>as above] (20) </td></tr></table></body></html>"}, "TABREF3": {"text": "Table 2. Donor demographics and ACE2 distribution scores for each tissue 626 region. 627", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Case # </td><td>Group </td><td>Age (yrs) </td><td>Sex </td><td>Comorbidities </td><td>Trachea </td><td>Bronchi </td><td>Bronchioles </td><td>Alveoli </td></tr><tr><td>1 </td><td>Control </td><td>5 </td><td>F </td><td>Trauma </td><td>NA </td><td>2 </td><td>2 </td><td>1 </td></tr><tr><td>2 </td><td>Control </td><td>57 </td><td>M </td><td>Arrhythmia </td><td>0 </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>3 </td><td>Control </td><td>31 </td><td>M </td><td>Stroke (Joubert syndrome) </td><td>1 </td><td>1 </td><td>0 </td><td>0 </td></tr><tr><td>4 </td><td>Control </td><td>53 </td><td>F </td><td>Trauma </td><td>NA </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>5 </td><td>Control </td><td>2 </td><td>M </td><td>Brain hemorrhage </td><td>0 </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>6 </td><td>Control </td><td>2 </td><td>M </td><td>Trauma </td><td>0 </td><td>0 </td><td>1 </td><td>2 </td></tr><tr><td>7 </td><td>Control </td><td>0.5 </td><td>M </td><td>Spinomuscular atrophy </td><td>NA </td><td>0 </td><td>1 </td><td>0 </td></tr><tr><td>8 </td><td>Control </td><td>71 </td><td>M </td><td>Stroke, Parkinson's disease, nonsmoker </td><td>0 </td><td>1 </td><td>1 </td><td>0 </td></tr><tr><td>9 </td><td>Control </td><td>4 </td><td>F </td><td>Trauma </td><td>0 </td><td>0 </td><td>0 </td><td>2 </td></tr><tr><td>10 </td><td>Control </td><td>1.2 </td><td>M </td><td>Trauma </td><td>0 </td><td>NA </td><td>1 </td><td>1 </td></tr><tr><td>11 </td><td>Control </td><td>53 </td><td>F </td><td>Trauma, nonsmoker </td><td>0 </td><td>0 </td><td>2 </td><td>0 </td></tr><tr><td>12 </td><td>Control </td><td>26 </td><td>F </td><td>NA </td><td>0 </td><td>NA </td><td>0 </td><td>0 </td></tr><tr><td>13 </td><td>Control </td><td>27 </td><td>F </td><td>NA </td><td>NA </td><td>0 </td><td>1 </td><td>0 </td></tr><tr><td>14 </td><td>Control </td><td>64 </td><td>M </td><td>NA </td><td>NA </td><td>1 </td><td>1 </td><td>0 </td></tr><tr><td>15 </td><td>Chronic disease </td><td>53 </td><td>F </td><td>Smoker </td><td>0 </td><td>NA </td><td>0 </td><td>1 </td></tr><tr><td>16 </td><td>Chronic disease </td><td>60 </td><td>M </td><td>COPD, smoker </td><td>NA </td><td>NA </td><td>0 </td><td>1 </td></tr><tr><td>17 </td><td>Chronic disease </td><td>32 </td><td>M </td><td>COPD, smoker </td><td>0 </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>18 </td><td>Chronic disease </td><td>68 </td><td>M </td><td>COPD </td><td>NA </td><td>1 </td><td>0 </td><td>1 </td></tr><tr><td>19 </td><td>Chronic disease </td><td>68 </td><td>F </td><td>COPD </td><td>NA </td><td>NA </td><td>1 </td><td>1 </td></tr><tr><td>20 </td><td>Chronic disease </td><td>9 </td><td>M </td><td>Asthma </td><td>0 </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>21 </td><td>Chronic disease </td><td>25 </td><td>F </td><td>Cystic fibrosis </td><td>NA </td><td>0 </td><td>0 </td><td>0 </td></tr><tr><td>22 </td><td>Chronic disease </td><td>47 </td><td>F </td><td>Cardiovascular disease </td><td>1 </td><td>2 </td><td>2 </td><td>1 </td></tr><tr><td>23 </td><td>Chronic disease </td><td>27 </td><td>M </td><td>Cystic fibrosis </td><td>0 </td><td>NA </td><td>NA </td><td>1 </td></tr><tr><td>24 </td><td>Chronic disease </td><td>50 </td><td>F </td><td>Cardiovascular disease, diabetes, asthma </td><td>NA </td><td>0 </td><td>0 </td><td>0 </td></tr><tr><td>25 </td><td>Chronic disease </td><td>37 </td><td>M </td><td>Drug use, smoker </td><td>0 </td><td>0 </td><td>0 </td><td>0 </td></tr><tr><td>26 </td><td>Chronic disease </td><td>38 </td><td>M </td><td>Asthma (status asthmaticus) </td><td>0 </td><td>0 </td><td>0 </td><td>0 </td></tr><tr><td>27 </td><td>Chronic disease </td><td>32 </td><td>M </td><td>Cystic fibrosis </td><td>NA </td><td>NA </td><td>0 </td><td>1 </td></tr><tr><td>28 </td><td>Chronic disease </td><td>58 </td><td>F </td><td>Cardiovascular disease, diabetes, NASH </td><td>0 </td><td>0 </td><td>0 </td><td>1 </td></tr><tr><td>29 </td><td>Chronic disease </td><td>19 </td><td>F </td><td>Cystic fibrosis </td><td>NA </td><td>0 </td><td>0 </td><td>0 </td></tr></table></body></html>"}, "TABREF4": {"text": "Table 3. Parameters for immunohistochemistry on fixed tissues. 634", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Target </td><td>Primary Antibody </td><td>Antigen Retrieval </td><td>Secondary Reagents </td></tr><tr><td>Allograft Inflammatory </td><td>Anti-AIF1 polyclonal (#019-19741, Wako </td><td>HIER, Citrate buffer pH 6.0, 110\u02daC for 15 </td><td>Dako EnVision+ System- HRP Labeled Polymer </td></tr><tr><td>Factor 1 (AIF1) </td><td>Pure Chemical Industries, Ltd., Richmond, VA USA) in diluent 1:1000 x 1 </td><td>min; 20 min cool down (Decloaking Chamber Plus, Biocare Medical, Concord, CA USA) </td><td>Anti-rabbit, 30 min (Dako North America, Inc., Carpentaria, CA USA) AEC chromogen, counterstain. </td></tr><tr><td>hour </td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>Angiotensin-\n</td><td>Anti-ACE2, </td><td>HIER, Citrate Buffer, </td><td>Dako EnVision+ System- </td></tr><tr><td>Converting Enzyme 2 (ACE2) </td><td>monoclonal (MAB933, R&amp;D Systems, </td><td>pH 6.0, 110\u02daC for 15 minutes; 20 min cool down (Decloaking Chamber Plus, Biocare Medical, Concord, CA </td><td>HRP Labeled Polymer Anti-mouse, 60 min (Dako </td></tr><tr><td>Minneapolis, MN USA) in diluent at 1:100 x 1 hour. </td><td>North America, Inc., Carpentaria, CA USA), DAB Chromogen, counterstain. </td></tr><tr><td>\u00a0</td><td>USA) </td></tr><tr><td>MUC5B </td><td>Rabbit anti-MUC5B polyclonal, (LSBio #LS-B8121, LifeSpan BioSciences, Inc., </td><td>HIER, Citrate buffer pH 6.0, 110\u02daC for 15min; 20 min cool down </td><td>Step 1: Biotinylated anti-Rabbit IgG (H+L) (Vector Laboratories, Inc., Burlingame, CA) in Dako </td></tr><tr><td>Seattle, WA) in Dako Antibody Diluent (Dako North America, Inc., Carpentaria, CA); 1:60,0000/30 min </td><td>\u00a0</td><td>Wash Buffer (Dako North America, Inc., Carpentaria, CA); 1:500, 30 min Step 2: Vectastain ABC Kit (Vector Laboratories, Inc., Burlingame, CA), 30min. DAB Chromogen, counterstain. </td></tr><tr><td>Surfactant Protein - C (SP-C) </td><td>Anti-SP-C, polyclonal (PA5-71680, Thermo Fisher Scientific, Waltham, MA USA) in diluent 1:100 x 1 hour </td><td>HIER, Citrate Buffer, pH 6.0, 110\u02daC for 15 minutes; 20 min cool down (Decloaking Chamber Plus, Biocare Medical, Concord, CA </td><td>Dako EnVision+ System- HRP Labeled Polymer Anti-rabbit, 60 min (Dako North America, Inc., Carpentaria, CA USA), AEC chromogen, counterstain. </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>\u00a0</td><td>USA) </td></tr></table></body></html>"}}, "back_matter": []}